Nikhil Prasad Fact checked by:Thailand Medical News Team Mar 05, 2025 16 hours, 26 minutes ago
Medical News: Lung cancer remains one of the leading causes of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) being the most common form. Despite advancements in treatments such as chemotherapy, immunotherapy, and targeted therapies, NSCLC remains challenging to treat due to its aggressive nature and high likelihood of metastasis. Researchers have long been exploring innovative ways to improve treatment outcomes by targeting not just the cancer cells but also the surrounding immune environment that plays a crucial role in cancer progression.
Vinorelbine Shows Potential in Transforming Immune Cells to Fight Lung Cancer
The Role of Tumor Associated Macrophages
A key component of the tumor microenvironment is a type of immune cell called tumor-associated macrophages (TAMs). These macrophages exist in two forms: M1 and M2. M1 macrophages have an anti-cancer role, helping to eliminate tumor cells. In contrast, M2 macrophages contribute to tumor growth, aiding in cancer cell invasion, metastasis, and suppression of the body's immune response.
Reprogramming M2 macrophages into M1 macrophages has been proposed as a promising strategy to enhance the body's ability to fight cancer. This
Medical News report highlights a recent study that explores how vinorelbine, a chemotherapy drug, can influence this transformation.
Study Conducted by Researchers at Ege University
A team of researchers from Ege University in Turkey conducted a study to investigate the effects of vinorelbine on M2 macrophages and NSCLC cells. The study aimed to determine whether vinorelbine could reprogram M2 macrophages into M1-like cells, thereby enhancing the anti-tumor immune response. The research team included experts from the Department of Basic Oncology, the Translational Pulmonary Research Group, and the Department of Pulmonary Medicine at Ege University.
Key Findings of the Study
The researchers first induced the transformation of M2 macrophages from peripheral blood mononuclear cells. They then treated these M2 macrophages with different concentrations of vinorelbine and analyzed their behavior.
-Reprogramming of Macrophages
The study found that vinorelbine, particularly at lower doses, successfully reprogrammed M2 macrophages to exhibit characteristics of M1 macrophages. This was evident from increased levels of CD80, a marker associated with M1 macrophages, and reduced levels of CD206 and CD163, which are markers of M2 macrophages.
-Impact on Cancer Cell Invasion
The researchers also observed that M2 macrophages promoted the invasion of lung cancer cells. However, when vinorelbine was introduced, it significantly reduced this invasive effect. This suggests that vinorelbine not only affects cancer cells directly but also modifies the tumor microenvironment to reduce cancer progression.
-Gene Expression Changes
Further analysis showed that M2 macrophages t
riggered the overexpression of several genes linked to tumor growth, immune suppression, and resistance to cell death. Vinorelbine counteracted these effects by reducing the expression of pro-tumor genes such as BCL2 while promoting genes associated with apoptosis (programmed cell death). Additionally, the drug was found to inhibit the activation of STAT3, a signaling molecule that plays a role in macrophage polarization and tumor survival.
-Inhibition of Cancer Cell Migration
To assess how vinorelbine affected the mobility of cancer cells, the researchers performed a wound healing assay. They found that cancer cells co-cultured with M2 macrophages showed increased migration, meaning they spread more rapidly. However, when vinorelbine was introduced, it significantly slowed down this migration, indicating its potential to suppress cancer metastasis.
Potential Implications for Cancer Treatment
The study highlights the potential of vinorelbine not only as a direct chemotherapy agent but also as a modifier of the immune system. By converting tumor-promoting M2 macrophages into anti-tumor M1 macrophages, vinorelbine may help improve immune responses against NSCLC. Moreover, using vinorelbine at lower doses could provide an effective strategy while minimizing side effects, making it a promising option for metronomic therapy (low-dose, continuous chemotherapy).
Conclusion
The findings from this research suggest that vinorelbine could enhance cancer treatment by targeting not only cancer cells but also the immune cells in the tumor environment. By reprogramming M2 macrophages into M1-like cells, vinorelbine has the potential to strengthen the body's natural defenses against NSCLC. Future clinical trials will be necessary to confirm these findings and determine how this approach can be integrated into current treatment strategies.
The study findings were published in the peer-reviewed International Journal of Molecular Sciences.
https://www.mdpi.com/1422-0067/26/5/2252
For the latest Cancer News, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/new-hope-for-lung-cancer-treatment-with-isorhapontigenin
https://www.thailandmedical.news/news/phytochemicals-from-pomegranate-peel-can-help-fight-lung-cancer-and-covid-19
https://www.thailandmedical.news/news/thai-scientists-from-khon-kaen-develop-ai-platform-for-accurate-lung-cancer-detection
https://www.thailandmedical.news/pages/thailand_doctors_listings
https://www.thailandmedical.news/pages/thailand_hospital_listings
Share
Tweet
Share
